Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer

Brief Summary

Official Title: “Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer”

The purpose of the study is to determine the optimal, lowest dose of radioactive tracer required for Positron Emission Mammography (PEM), and the accuracy and reliability of PEM in pre-surgical evaluations for patients with newly diagnosed breast cancer anticipating breast-conserving surgery but identified to have a second unsuspected breast cancer by MRI.

  • Study Type: Interventional
  • Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
  • Study Primary Completion Date: March 2015

Detailed Clinical Trial Description

The purpose of this research in Phase 1 is to determine the lowest dose of radionuclide 18F-FDG that can be used in the Diagnostic use of Positron Emission Mammography for the diagnosis of multifocal breast cancer in patients wishing to have Breast Conservation Surgery for newly diagnosed breast cancer. Low dose injections (radioactive counts) of 18F-FDG will be compared to the equivalent radioactive counts for the standard higher dose 10 millicuries used in standard PEM studies in current clinical practice. Images will be post processed by computer aided software and will be placed in two categories: Low dose group, and higher dose group. Images will be randomly blinded to readers to assess the ability to see positive lesions that warrant further biopsy or to include in current surgical planning prior to breast conservation surgery or mastectomy. Images will be assessed for ability to see the PEM positive lesions on the lower dose images and this will be compared to the ability to see the PEM positive lesions on the standard higher dose images. Each of three breast cancer categories will be assessed Infiltrating Ductal Carcinoma, Lobular infiltrating Carcinoma, and Ductal Carcinoma Insitu. Phase 1 will have 30 patients.

The purpose of the research in Phase 2 is to use the lowest dose identified in Phase 1 for imaging primary breast cancer patients who have been identified by breast MRI to have an unsuspected second lesion of the breast not expected from Mammography or Ultrasound that requires biopsy for diagnosis prior to the biopsy to compare the reliability of PEM and MRI for identifying breast cancer at the 2nd site. Parameters assessed will include standard statistical analysis for sensitivity, specificity, positive predictive value and negative predictive value for MRI and PEM imaging with the new lower radionuclide dose selected by Phase 1. Phase 2 will have 100 patients.

Interventions Used in this Clinical Trial

  • Device: Positron Emission Mammography (PEM)
    • Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: Positron Emission Mammography (PEM)
    • Positron Emission Mammography (PEM)

Outcome Measures for this Clinical Trial

Primary Measures

  • PEM identification of primary breast cancer.
    • Time Frame: Upon study completion (~3 years)
      Safety Issue?: No

Secondary Measures

  • Lowest dose of F18-FDG giving optimal PEM imaging of primary breast cancers.
    • Time Frame: After the first 30 subjects (~one year)
      Safety Issue?: No
  • Identification of 2nd unsuspected primary breast cancer by PEM in patients with known index primary breast cancer.
    • Time Frame: Upon study completion (~3 years)
      Safety Issue?: No
  • Comparison of PEM and MRI for identification of index primary breast cancer and unsuspected primary breast cancer.
    • Time Frame: Upon study completion (~3 years)
      Safety Issue?: No
  • Comparison of PEM and MRI for identification of breast lesions that require biopsy but are not an unsuspected 2nd primary breast cancer in patients with known index primary breast cancer.
    • Time Frame: Upon study completion (~3 years)
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Must be 18 years of age or older
  • Newly diagnosed primary breast cancer
  • Must have a breast or breast/chest MRI ordered as part of standard of care
  • Must meet one or more of the following in Part 1:
  • T1 carcinoma of the breast appropriate for breast conserving surgery diagnosis established by core biopsy
  • Tis (ductal carcinoma in situ) carcinoma > 2 cm diameter
  • Invasive lobular carcinoma of the breast
  • Must meet the following in Part 2:
  • Known invasive or in situ primary breast cancer identified on pre-surgical breast MRI to have an unsuspected 2nd lesion recommended for biopsy and biopsy has not yet been performed

Exclusion Criteria

  • Known diabetes mellitus

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • Swedish Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • J. David Beatty, MD, Principal Investigator, Swedish Medical Center Cancer Institute

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01241721